Management of KCNQ1‑Related Long QT Syndrome (LQT1)

Epidemiology & Genetic Basis

Pathogenic KCNQ1 mutations cause LQT1, the most common congenital long‑QT subtype, accounting for approximately 40–50 % of genetically confirmed cases. 1

A corrected QT interval (QTc) ≥ 500 ms, measured with the tangent method in lead II or V5, defines high‑risk status for torsades de pointes and mandates urgent intervention. 2
Serum electrolytes should be obtained promptly, targeting potassium > 4.5 mmol/L, magnesium > 2.0 mg/dL, and calcium within the normal range, because abnormalities markedly increase arrhythmic risk even in congenital LQTS. 2

Perform a comprehensive medication review using crediblemeds.org to identify and discontinue all QT‑prolonging drugs (e.g., macrolide antibiotics, fluoroquinolones, citalopram, escitalopram, haloperidol, ondansetron, methadone). 2
Lifelong avoidance of all QT‑prolonging medications is essential for patients with KCNQ1 mutations. 2

High‑risk drug classes to avoid and suggested alternatives:

Class	Drugs to Avoid	Suggested Substitutes
Antibiotics	Erythromycin, Ciprofloxacin	Penicillins, Cephalosporins
Antidepressants	Citalopram, Escitalopram	Sertraline, Paroxetine
Antiarrhythmics	Sotalol, Dofetilide, Amiodarone, Procainamide	–

Nadolol 1–1.5 mg/kg once daily is the preferred beta‑blocker for LQT1 because non‑selective agents provide superior arrhythmia protection compared with β1‑selective agents. 2
Propranolol 2–4 mg/kg/day divided three times daily is an acceptable alternative, particularly in neonates and infants. 2
Bisoprolol may be used when tolerability is an issue, although nadolol remains the agent of choice. 2
Even asymptomatic carriers of pathogenic KCNQ1 variants with a normal QTc should be considered for beta‑blocker therapy. 1

Patients should avoid swimming and vigorous exercise, the primary triggers for arrhythmic events in KCNQ1‑related LQT1. 2
Exercise‑induced syncope is the hallmark presentation of LQT1, typically occurring during physical exertion or emotional stress. 2

Implantable cardioverter‑defibrillator (ICD) implantation is recommended for LQT1 patients with a prior cardiac arrest. 1
ICD should also be considered for patients who experience syncope or ventricular tachycardia despite adequate beta‑blocker therapy. 1
ICD may be contemplated in asymptomatic KCNQ1 carriers when QTc > 500 ms, although this threshold is more commonly applied to other genotypes. 1
Left cardiac sympathetic denervation (LCSD) is indicated when beta‑blockers are ineffective, not tolerated, or contraindicated, and also when ICD therapy is contraindicated, refused, or when multiple ICD shocks occur. 1

All first‑degree relatives should undergo ECG and clinical evaluation when a pathogenic KCNQ1 mutation is identified. 2
Provide patients and families with access to crediblemeds.org (website and smartphone app) for ongoing reference on QT‑prolonging medications. 2

Breastfeeding is generally recommended for infants with congenital LQTS, but maternal medications must be reviewed to ensure no QT‑prolonging agents are transferred via breast milk. 2
In infants receiving beta‑blockers, prolonged fasting should be avoided because beta‑blockers can mask symptoms of hypoglycemia. 2

Administer intravenous magnesium sulfate 2 g immediately, regardless of the patient’s serum magnesium level. 2
Correct bradycardia promptly with temporary pacing or isoproterenol infusion to prevent pause‑dependent triggers of torsades. 2
Avoid amiodarone and procainamide, as they further prolong the QT interval and can exacerbate torsades de pointes. 2